- This topic has 1 reply, 2 voices, and was last updated 1 year, 10 months ago by .
Viewing 1 reply thread
-
Posts
-
-
Parkinson´s disease (PD) patients often receive combined pharmacotherapies where D2-class dopamine agonists are used as an adjunct to L-DOPA. We have now investigated the effects of this adjunct treatment at multiple levels and obtained some intriguing results…read the entire story in this paper:
Dopamine Agonist Cotreatment Alters Neuroplasticity and Pharmacology of Levodopa-Induced Dyskinesia.
Espa E, Song L, Skovgård K, Fanni S, Cenci MA. Mov Disord. 2023 Jan 19. doi: 10.1002/mds.29301. Online ahead of print.
PMID: 36656044 -
Thank you for sharing this publication Angela!
-
Viewing 1 reply thread
- You must be logged in to reply to this topic.
